Target therapy: New drugs or new combinations of drugs in malignant pleural mesothelioma

Research output: Contribution to journalReview articlepeer-review


Malignant pleural mesothelioma (MPM) is a disease with a poor prognosis due to its aggressive nature. The management of patients with MPM is controversial. Considering that the contribution of surgery and radiation therapy in the management of this disease is not yet established, systemic treatments are predominantly considered during the course of MPM. Unfortunately, the currently therapeutic armamentarium is scarce and its outcomes still appear modest. New treatment strategies are needed. In preclinical setting, cell cycle regulation, apoptosis, growth factor pathways, and angiogenesis pathways involved in the development of MPM have been identified. However, in clinical setting, several drugs targeting these pathways resulted without a significant activity. A deeper knowledge of the biology and pathogenesis of this disease is required to develop more effective tools for diagnosis, therapy and prevention. This paper reviews therapeutic advances in MPM, with a particular focus on new drugs and new association of drugs of target therapy.

Original languageEnglish
Pages (from-to)S311-S321
JournalJournal of Thoracic Disease
Publication statusPublished - Jan 1 2018


  • Malignant pleural mesothelioma (MPM)
  • New association of drugs
  • New drugs
  • Target therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Target therapy: New drugs or new combinations of drugs in malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this